13D Filing: Birchview Capital and Yield10 Bioscience Inc. (YTEN)

SECURITIES
AND EXCHANGE COMMISSION

Washington,
DC 20549

 

 

SCHEDULE
13D

(Rule 13d-101)

 

INFORMATION
TO BE INCLUDED IN STATEMENTS FILED PURSUANT

TO RULE 13d-l(a)
AND AMENDMENTS THERETO FILED PURSUANT

TO RULE 13d-2(a)

(Amendment
No. 2)*

 

 

Yield10
Bioscience, INC

(Name of
Issuer)

 

COMMON STOCK,
$0.01 PAR VALUE PER SHARE

(Title of
Class of Securities)

 

98585K201

(CUSIP Number)

 

Matthew Strobeck

c/o Birchview Capital

688
Pine Street, Suite D

Burlington,
VT 05401

(802) 923-3080

(Name, Address
and Telephone Number of Person Authorized to Receive Notices and Communications)

 

December
21, 2017

(Date of
Event Which Requires Filing of This Statement)

If
the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D,
and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box.  ¨

(Continued on
the following pages)

(Page
1 of 12 Pages)

*

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information
required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of section 18 of
the Securities Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act.